COMMUNIQUÉS West-GlobeNewswire

Alvotech announces FDA acceptance of Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio®
08/06/2026
REYKJAVIK, Iceland, June 08, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, [...]
Intravacc met en avant ses capacités analytiques intégrées destinées à accélérer le développement de vaccins et de produits biologiques
08/06/2026
Ses services analytiques de pointe accompagnent les partenaires à chaque étape, de la caractérisation des produits et du développement des tests à la mise en conformité aux BPF et à la fabrication clinique Intravacc [...]
Press Release: Sanofi’s Sarclisa subcutaneous approved in the EU as the first anticancer treatment administered via an on-body injector
08/06/2026
Sanofi’s Sarclisa subcutaneous approved in the EU as the first anticancer treatment administered via an on-body injector Sarclisa administered via the CirCLIQ ® OBI offers a treatment experience designed around the [...]
IBA signe un contrat pour installer deux solutions de protonthérapie Proteus®ONE avec un grand centre médical universitaire aux États-Unis
08/06/2026
Louvain-la-Neuve, Belgique, le 8 juin 2026 - IBA (Ion Beam Applications S.A., EURONEXT), leader mondial des technologies d’accélération de particules et principal fournisseur de solutions de protonthérapie pour le [...]
Rappel : les BSA Nicox de juin 2024 expireront le 19 juin 2026
08/06/2026
Communiqué de presse Rappel : les BSA Nicox de juin 2024 expireront le 19 juin 2026 8 juin 2026 – publication à 7H30 Sophia Antipolis, France Nicox SA (Euronext Growth Paris : FR0013018124, ALCOX, éligible PEA-PME), une [...]
IBA signs contract with a major U.S. academic medical center to install two Proteus®ONE proton therapy solutions
08/06/2026
Louvain-La-Neuve, Belgium, June 08, 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment [...]
Communiqué de presse : Sarclisa en formulation sous-cutanée de Sanofi approuvé dans l’UE comme premier traitement anticancéreux administré via un injecteur portable
08/06/2026
Sarclisa en formulation sous-cutanée de Sanofi approuvé dans l’UE comme premier traitement anticancéreux administré via un injecteur portable Sarclisa administré via l’injecteur portable CirCLIQ ® offre une expérience [...]
Vivoryon Therapeutics N.V. to Report Q1 2026 Financial Results on June 11, 2026
08/06/2026
Vivoryon Therapeutics N.V. to Report Q1 2026 Financial Results on June 11, 2026 Halle (Saale) / Munich, Germany, June 8, 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) ( Vivoryon ), a clinical [...]
Reminder: Nicox June 2024 Warrants will expire June 19, 2026
08/06/2026
Press Release Reminder: Nicox June 2024 Warrants will expire June 19, 2026 June 8, 2026 – release at 7:30 am CET Sophia Antipolis, France Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international [...]
Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology
08/06/2026
Strategic collaboration combines Nurix’s leadership in targeted protein degradation with Roche’s portfolio of B-cell targeted therapies and global clinical and commercialization footprint Robust clinical development [...]
Roche announces global collaboration with Nurix Therapeutics to co-develop and co-commercialise potential best-in-class BTK degrader bexobrutideg across malignant haematology, immunology and neurology
08/06/2026
Agreement offers potential best-in-class targeted protein degrader therapy option for people living with B-cell malignancies Collaboration adds to Roche’s oncology pipeline and offers potential indications in immunology [...]
LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater China
08/06/2026
The New Drug Application for LNZ100 in China was submitted September 2025 with approval anticipated in Q1 2027 SAN DIEGO, June 07, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ, “LENZ” or the “Company [...]
GNI Group to Acquire Ayumi Pharmaceutical Holdings, Expanding Its Position as a Global Biopharmaceutical Company
08/06/2026
Transaction Establishes a Large-Scale Pharmaceutical Platform in Japan and Strengthens Commercial Capabilities Across Key Therapeutic Areas TOKYO, June 07, 2026 (GLOBE NEWSWIRE) -- GNI Group Co., Ltd. (TSE: 2160) today [...]
Antag Therapeutics presents positive Phase 1 results at the 2026 Scientific Sessions of the American Diabetes Association for AT7687, a first-in-class GIPR antagonist
07/06/2026
AT7687 demonstrated a favorable safety and tolerability profile with no adverse GI tolerability signals identified Once-weekly dosing potential and demonstrated target engagement across the doses tested were confirmed [...]
Boehringer Ingelheim’s survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis, supporting improved metabolic health in people living with obesity
07/06/2026
News builds on previously announced positive topline results from SYNCHRONIZE-1 76-week trial, which met its primary endpoints and showed up to 16.6% weight loss with survodutide, a novel glucagon/GLP-1 dual agonist, [...]
Zealand Pharma announces Boehringer Ingelheim's survodutide Phase III trial in people living with obesity showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis
07/06/2026
Company announcement No. 21 / 2026 Zealand Pharma announces Boehringer Ingelheim's survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified [...]
Real-World Evidence of Eversense 365 Presented at ADA Demonstrating Strong Performance and Patient Impact in Both Open and Closed Loop Systems
06/06/2026
Eversense 365 delivered favorable glucometrics compared to other open and closed loop systems, validating the one-year CGM’s differentiated approach and high performance New data expands on findings shared at ATTD and [...]
Her Bodhi Claims Evaluated: What Research Reveals About This Primal Queen Alternative, Weight Loss Support and Consumer Reviews
06/06/2026
An independent, research-informed evaluation of the Her Bodhi botanical formula — examining its ingredient benefits, weight loss positioning, menopause wellness support, disclosed side effects, and publicly available [...]
SKG Launches PS700 Neck Massager, Bringing Deep Kneading, Layered Heat, and Immersive Audio to Everyday Recovery
06/06/2026
The new wearable recovery device pairs deep-kneading massage, layered warmth, and immersive audio to help ease neck tension NEW YORK, June 06, 2026 (GLOBE NEWSWIRE) -- For many people, neck tension can return by the [...]

Pages